الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
Serum procollagen type III peptide was believed to
reflect synthesis and degradation of type III collagen
during fibrogenesis. Accumulation of type III procollagen
in the liver and increase of its serum level in some hepatic
diseases have been previously recorded.
The aim of this work is to evaluate the significance of
serum PIlI P assay in inflammatory and fibrogenic activity
in children with chronic liver disease and to study the
possibility of replacing liver biopsy by simple non invasive
serum assay of procollagen III peptide.
In this work, 26 patients with chronic liver diseases
CLD. were studied. Patients were divided into two groups
(according to histopathological examination of liver biopsy)
chronic active hepatitic group CAH (13 patients) and chronic
persistent hepatitic group CPH (13 patients). Their ages
ranged from three to thirteen years, ten healthy subjects
were included as a control group.
All cases were subjected to full medical history, full
clinical examination and liver biopsy. The following
investigations were done: Hemoglobin percent, ESR, serum
albumin, albumin/globulin, total bilirubin. SGOT, SGPT,
80
alkaline phosphatase, HBs Ag in addition to procollagen III
peptide (PII I p)
The results of this study showed that serum levels of
PIlI P in patients with CAH were significantly higher than
the control group (P < 0.001). There was also significant
elevation of PIlIP in patients with CPH compared to control
group (P < 0.05). Although both patient groups showed
significant elevation of PIlI P level than the control group
CAH showed a higher elevation than CPH.
There was significant elevation of bilirubin, SGOT and
SGPT in the two groups of patients as compared to the
control group.
There was no correlation found between serum PIlI P and
liver function tests.
from this work we can conclude that Serum PIlI P is a
relatively simple, non invasive, dynamic marker for hepatic
fibrogenesis and inflammation. However further studies on
wide scale in field of chronic liver diseases with different
etiologies are needed to estimate serum PIlI P in the same
patient during the various stages of the disease. This
might help to evaluate the usefulness of serum PIlI P assay
in monitoring the disease.